Kymera Therapeutics Menu Inventing New Medicines Pioneering Targeted Protein Degradation News & Events 11/17/21 Kymera Therapeutics to Host Virtual R&D Day on December 16, 2021 Read More 11/12/21 Kymera Therapeutics Presents New Preclinical Data on STAT3 Degraders at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting Read More VIEW ALL Targeted Protein Degradation A New Way to Treat Disease Kymera is a clinical stage biopharmaceutical company developing novel protein degrader therapeutics to treat disease in powerful new ways, which harness the body’s natural protein degradation system to selectively degrade disease causing proteins with the goal of completely removing them from the body. Kymera is driven to invent transformative medicines for a wide variety of diseases where traditional drug modalities have failed to sufficiently unlock the appropriate biological solution. MORE ABOUT US A Powerful Drug Discovery Engine Kymera has developed a proprietary targeted protein degradation platform called Pegasus which enables the design of highly selective small molecule protein degraders – heterobifunctional molecules with potent activity against disease-causing proteins. Thanks to our Whole Body E3 Ligase Atlas, Pegasus is expanding the universe of potential disease targets and possible treatments. OUR PEGASUS PLATFORM Promising New Therapies We are rapidly advancing a broad and diverse pipeline of novel protein degraders. These are medicines designed to target high impact, previously undrugged or insufficiently drugged targets within validated biological pathways. Further, our strategic partnerships with other leading companies and organizations are allowing us to expand the reach of our protein degrader medicines to treat more patients and diseases. OUR PIPELINE Kymera Therapeutics KYMERA THERAPEUTICS 200 Arsenal Yards Blvd., Suite 230 Watertown, MA 02472 Careers Contact Us Terms of Service Privacy Policy